Tesamorelin (Egrifta)
FDA APPROVEDA growth hormone-releasing hormone (GHRH) analog specifically approved for reducing visceral adipose tissue (deep belly fat).
How It Works
Stimulates the pituitary gland to produce growth hormone, which mobilizes visceral fat stores while preserving muscle mass. Targets the metabolically dangerous fat around organs.
Benefits
- ✓Reduction in visceral abdominal fat
- ✓Preserved lean muscle mass
- ✓Improved body composition
- ✓Potential cardiovascular benefits
- ✓Enhanced metabolic profile
Potential Side Effects
- ⚠Injection site reactions
- ⚠Joint pain
- ⚠Peripheral edema
- ⚠Elevated IGF-1 levels
- ⚠Potential glucose intolerance
FDA Status
FDA-approved for HIV-associated lipodystrophy; used off-label for visceral fat reduction
Clinical Evidence
Clinical trials show significant reduction in trunk fat in HIV patients. Growing evidence for off-label use in metabolic syndrome.
Common Dosage
2mg daily subcutaneous injection
⚠ Always consult with a healthcare professional before starting any new supplement or treatment.
Related Products
CJC-1295
A GHRH analog (Growth Hormone Releasing Hormone) that stimulates the pituitary gland to release growth hormone in pulses.
Ipamorelin
A GHRP analog that stimulates growth hormone release via ghrelin receptors, often paired with CJC-1295.
AOD-9604
A modified fragment of human growth hormone (HGH fragment 176-191) designed to have fat-burning effects without the other effects of full HGH.
Medical Disclaimer
The information provided on this page is for educational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional before starting any new treatment, supplement, or making changes to your health regimen.